Abstract

Gastrointestinal stromal tumor (GIST) account for 1% of all gastrointestinal neoplasms and are the most common mesenchymal tumor of gastrointestinal tract. There are considered to originate fom the intestinal cell of Cajal, an intestinal pacemaker cell, characterized usually express the KIT protein on immunohistochemistry. The stomach (40-60%) and small intestine (30-40%) are the most common locations. Diagnosis of these tumors is difficult to establish, because symptoms are vague and traditional diagnostic tests are not specific. GISTs shows a wide variety of clinical behaviours ranging fom benign to frankly malignant, making the outcome totally unpredictable. Surgery is the standard treatment of local GIST while Imatinib (tyrosine kinasi inhibitor) is considered as the standard treatment of metastatic disease. Resistence to Imatinib is also becoming a major clinical problem but new tirosyne kinase inibitor are being studied to improve the treatment and survival. The present paper is a review of the salient features of epidemiology, pathophysiology, diagnosis, therapy and prognostic factors of GIST
Titolo tradotto del contributo[Autom. eng. transl.] [Gastrointestinal stromal tumors]
Lingua originaleItalian
pagine (da-a)97-109
Numero di pagine13
RivistaANNALI ITALIANI DI CHIRURGIA
Volume82
Stato di pubblicazionePubblicato - 2011

Keywords

  • Antineoplastic Agents
  • Digestive System Surgical Procedures
  • Disease Progression
  • Gastrointestinal Stromal Tumors
  • Humans
  • Indoles
  • Intestinal Neoplasms
  • Italy
  • Piperazines
  • Prognosis
  • Pyrimidines
  • Pyrroles
  • Risk Factors
  • Stomach Neoplasms
  • Treatment Outcome

Fingerprint

Entra nei temi di ricerca di '[Gastrointestinal stromal tumors]'. Insieme formano una fingerprint unica.

Cita questo